Our analyses suggested there was no significant association between SGLT2 inhibitors and chronic lower respiratory disease (HR, 1.04; 95% CI, 0.97-1.13) (eFigure 5a in the Supplement). Here, SLC5A2 is linked to lower respiratory tract disorder.